Pharmaceutical Industry

The bill would allow terminally ill patients the right to try experimental treatments that have not been approved when no alternatives exist. (iStock photo)

Healthcare

Senate passes bill to give terminally ill patients access to experimental drugs

Robert King -

August 3, 2017 4:18 pm

Premiums for Medicare's Part D prescription drug program are expected to slightly decline in 2018, the first drop in five years, the Trump administration said Wednesday. (AP Photo/Jon Elswick)

Healthcare

Medicare Part D premiums set to drop next year

Robert King -

August 2, 2017 9:43 pm

It is clear that neither party is willing to work with the other in order to create a better healthcare alternative. All the while, patients are suffering -- limited access and expensive premiums have isolated many. (C-SPAN2 via AP)

Beltway Confidential

Broken promises: Congress has let down patients and doctors in failing to fix Obamacare

Kevin Campbell -

July 25, 2017 9:50 pm

Rather than giving companies new tax breaks or a cut in their overall tax rate, the focus of tax reform should be to completely clean out the code of all the special interest tax breaks and loopholes that companies such as Mylan take advantage of. (Victor J. Blue/Bloomberg)

Business

Mylan: The poster child of what is wrong with the tax code

Washington Examiner Staff -

July 24, 2017 4:01 am

Economy

Trump touts ‘Made in America’

Josh Siegel -

July 21, 2017 10:40 pm

Heather Bresch, chief executive officer of Mylan NV, holds up Mylan EpiPen medication during a House Oversight and Government Reform Committee hearing on Sept. 21, 2016. Lawmakers questioned Bresch about why the company raised the price of the life-saving injection to $600 for a two-pack, from $57 a shot when it took over sales of the product in 2007. (Andrew Harrer/Bloomberg)

Healthcare

Maryland ‘price gouging’ law meets immediate legal challenge

Kimberly Leonard -

July 17, 2017 4:01 am

The problem here is very clear: How can public policy lower the price of prescription drugs? The answer, however, differs greatly depending on who you ask. (iStock photo)

Beltway Confidential

Letting the government ‘negotiate’ with drug companies is just window dressing for price controls

Brandon Arnold -

July 13, 2017 4:22 pm

Lawmakers passed a bill that would let the FDA continue to collect user fees from drug and device makers, with the agency using that revenue to speed up approval of new products. (AP Photo/Andrew Harnik)

Healthcare

House advances FDA funding bill

Robert King -

July 12, 2017 6:40 pm

n the vacuum, Republicans are working to speed up approval of generic drugs in particular to offer more competition and lower prices. Democrats don't like that route because lower prices wouldn't be guaranteed.

Healthcare

Democrats disappointed Trump hasn’t worked to lower drug prices

Robert King -

June 26, 2017 4:01 am

It's no surprise that marketing works. (AP Photo/Sue Ogrocki, File)

Op-Eds

Are Big Pharma gifts to physicians an expensive problem, or a red herring?

Brian Joondeph -

June 23, 2017 12:00 pm

1...107108109...156 Page 108 of 156

Tag: Pharmaceutical Industry

Senate passes bill to give terminally ill patients access to experimental drugs

Medicare Part D premiums set to drop next year

Broken promises: Congress has let down patients and doctors in failing to fix Obamacare

Mylan: The poster child of what is wrong with the tax code

Trump touts ‘Made in America’

Maryland ‘price gouging’ law meets immediate legal challenge

Letting the government ‘negotiate’ with drug companies is just window dressing for price controls

House advances FDA funding bill

Democrats disappointed Trump hasn’t worked to lower drug prices

Are Big Pharma gifts to physicians an expensive problem, or a red herring?

NEWS

POLICY

COMMENTARY

RESTORING AMERICA